Table of Contents

company-logo

Oncternal Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development of oncology therapies for cancers with critical unmet medical needs. The company's clinical pipeline includes zilovertamab, a humanized monoclonal antibody that binds to receptor-tyrosine kinase-like Orphan Receptor 1 (ROR1); and ONCT-216, a small molecule inhibiting the biological activity of ETS-family transcription factor oncoproteins. It is also developing ONCT-808, a chimeric antigen receptor T-cells (CAR-T) product candidate that targets ROR1; and ONCT-534, a dual-action androgen receptor inhibitor product candidate for the treatment of castration-resistant prostate and other androgen receptor-driven cancers. Oncternal Therapeutics, Inc. has license agreements with the Regents of the University of California; Georgetown University; The University of Texas MD Anderson Cancer Center; Shanghai Pharmaceutical (USA) Inc.; and University of Tennessee Research Foundation. Oncternal Therapeutics, Inc. has a research collaboration with Celularity Inc. to evaluate placental derived-cellular therapies targeting ROR1. The company is headquartered in San Diego, California.

Oncternal Therapeutics Dividend Announcement

• Oncternal Therapeutics does not currently offer dividends, we're keeping a close eye on its growth potential and financial developments.
• Stay tuned for updates on Oncternal Therapeutics dividend policy and future announcements. In the meantime, explore other dividend-yielding opportunities on our website.

Oncternal Therapeutics Dividend History

Oncternal Therapeutics Dividend Yield

Oncternal Therapeutics current trailing twelve-month (TTM) dividend yield is -%. Interested in purchasing Oncternal Therapeutics stock? Use our calculator to estimate your expected dividend yield:

Oncternal Therapeutics Financial Ratios

P/E ratio-0.11
PEG ratio-0.01
P/B ratio0.42
ROE-177.58%
Payout ratio0.00%
Current ratio2.39
Quick ratio2.39
Cash Ratio2.03

Oncternal Therapeutics Dividend FAQ

Does Oncternal Therapeutics stock pay dividends?
Oncternal Therapeutics does not currently pay dividends to its shareholders.
Has Oncternal Therapeutics ever paid a dividend?
No, Oncternal Therapeutics has no a history of paying dividends to its shareholders. Oncternal Therapeutics is not known for its dividend payments.
Why doesn't Oncternal Therapeutics pay dividends?
There are several potential reasons why Oncternal Therapeutics would choose not to pay dividends to their shareholders:

1. Growth opportunities: Companies, especially in fast-growing industries like technology, reinvest earnings into expansion, R&D, or acquisitions to fuel future growth and increase company value.

2. Tax implications: Not paying dividends can reduce the tax burden on shareholders, who may prefer to defer taxes until selling shares and realizing capital gains.

3. Investor preferences: Some investors prefer companies to reinvest profits for higher long-term returns, particularly those seeking capital appreciation over income.

4. Capital allocation priorities: Companies may allocate cash to pay down debt, fund share buybacks, or invest in projects with higher returns than dividends.

5. Market expectations: In certain sectors, like technology, reinvesting profits for growth and innovation is often prioritized over distributing dividends to shareholders.
Will Oncternal Therapeutics ever pay a dividend?
The decision for a company to pay dividends depends on various factors including its financial performance, growth prospects, capital allocation priorities, and shareholder preferences. While Oncternal Therapeutics has not paid dividends historically and has instead focused on reinvesting its earnings for growth, it's ultimately up to the company's management and board of directors to decide whether to initiate a dividend policy in the future.
Is Oncternal Therapeutics a dividend aristocrat?
Oncternal Therapeutics is not considered a Dividend Aristocrat. The term "Dividend Aristocrat" is typically used to describe a company in the S&P 500 index that has increased its dividend payouts for at least 25 consecutive years.
Is Oncternal Therapeutics a dividend king?
Oncternal Therapeutics is not classified as a "Dividend King". A Dividend King is a company that has managed to increase its dividend payouts for 50 consecutive years or more, which is an even more selective group than the Dividend Aristocrats.
Is Oncternal Therapeutics a dividend stock?
No, Oncternal Therapeutics is not considered a dividend stock. A dividend stock is a stock of a company that regularly pays out dividends to its shareholders.
How to buy Oncternal Therapeutics stocks?
To buy Oncternal Therapeutics you need a brokerage account. Open an account with a reputable brokerage firm that offers access to the stock market. Consider factors such as fees and account minimums.

Place an order: Use the brokerage's trading platform to place an order to buy Oncternal Therapeutics stock.

Remember that buying stocks involves risk, and it's important to carefully consider your investment goals, risk tolerance, and conduct thorough research before making any investment decisions.